JP2019504830A - Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体 - Google Patents

Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体 Download PDF

Info

Publication number
JP2019504830A
JP2019504830A JP2018535293A JP2018535293A JP2019504830A JP 2019504830 A JP2019504830 A JP 2019504830A JP 2018535293 A JP2018535293 A JP 2018535293A JP 2018535293 A JP2018535293 A JP 2018535293A JP 2019504830 A JP2019504830 A JP 2019504830A
Authority
JP
Japan
Prior art keywords
difluoromethoxy
quinazolin
enamide
cancer
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018535293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504830A5 (enExample
Inventor
スラッシー、アブデルマリック
ダブ、ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of JP2019504830A publication Critical patent/JP2019504830A/ja
Publication of JP2019504830A5 publication Critical patent/JP2019504830A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018535293A 2016-01-06 2017-01-06 Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体 Withdrawn JP2019504830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275376P 2016-01-06 2016-01-06
US62/275,376 2016-01-06
PCT/CA2017/050015 WO2017117680A1 (en) 2016-01-06 2017-01-06 Novel fluorinated quinazoline derivatives as egfr inhibitors

Publications (2)

Publication Number Publication Date
JP2019504830A true JP2019504830A (ja) 2019-02-21
JP2019504830A5 JP2019504830A5 (enExample) 2020-02-20

Family

ID=59273095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535293A Withdrawn JP2019504830A (ja) 2016-01-06 2017-01-06 Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体

Country Status (7)

Country Link
US (1) US20190016689A1 (enExample)
EP (1) EP3400216A4 (enExample)
JP (1) JP2019504830A (enExample)
CN (1) CN108779079A (enExample)
AU (1) AU2017204973A1 (enExample)
CA (1) CA3008312A1 (enExample)
WO (1) WO2017117680A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3687981A4 (en) * 2017-09-26 2021-03-31 The Regents of the University of California COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
CN113811528A (zh) 2019-03-15 2021-12-17 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
US20220229072A1 (en) 2019-06-04 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
AU2020395185A1 (en) * 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111548314B (zh) * 2020-05-22 2021-09-03 上海万巷制药有限公司 一种n-(3-氯-4-氟苯基)-7-氟-6-硝基-4-喹唑啉胺的生产方法
CN116096710B (zh) 2020-06-09 2025-07-25 阿雷生物药品公司 用于治疗braf相关疾病和障碍的4-氧代-3,4-二氢喹唑啉酮化合物
CN113264888A (zh) * 2021-03-04 2021-08-17 江苏康可得生物技术股份有限公司 酪氨酸激酶抑制剂及其药物应用
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
WO2023128350A1 (ko) * 2021-12-30 2023-07-06 주식회사 비투에스바이오 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746999B1 (en) * 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
CN102731485B (zh) * 2011-04-02 2016-06-15 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
JP2014532063A (ja) * 2011-10-12 2014-12-04 テリジェン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ キナーゼ阻害剤としてのキナゾリン誘導体およびその使用方法
CN104350049B (zh) * 2012-05-07 2016-07-13 苏州韬略生物科技有限公司 作为激酶抑制剂的取代氨基喹唑啉
CN104910140A (zh) * 2014-03-14 2015-09-16 齐鲁制药有限公司 喹唑啉类化合物、其制备方法及应用
US10196365B2 (en) * 2014-08-15 2019-02-05 Arromax Pharmatech Co., Ltd. Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
US20190016689A1 (en) 2019-01-17
CN108779079A (zh) 2018-11-09
EP3400216A1 (en) 2018-11-14
WO2017117680A1 (en) 2017-07-13
EP3400216A4 (en) 2019-08-14
AU2017204973A1 (en) 2018-07-12
CA3008312A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
JP2019504830A (ja) Ｅｇｆｒ阻害剤としての新規フッ素化キナゾリン誘導体
US9382235B2 (en) Unsolvated crystalline form 1 of N-[5-(3, 5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide and methods of use thereof
CN104903321B (zh) 作为激酶抑制剂的经取代三环苯并咪唑
RU2743074C2 (ru) Соединения, активные по отношению к бромодоменам
JP2018504441A (ja) 癌の治療に有用なｅｇｆｒ阻害剤としての新規フッ素化誘導体
WO2017167182A1 (zh) 一种选择性的c-kit激酶抑制剂
CN103930425A (zh) 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CA2902132C (en) Quinazolines as kinase inhibitors
KR20180132618A (ko) 아미노티아졸 화합물 및 이의 용도
TW201326143A (zh) Ｇ蛋白偶合ｍａｓ受體之調節劑及與其相關病症之治療
ES2300775T3 (es) Furazanobencimidazoles.
CA2973773A1 (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
JP2025160244A (ja) １－チアゾール－２－イル－ピラゾール－５－カルボン酸誘導体の結晶多形
TW201305130A (zh) 突變雄激素受體拮抗藥
CN111138426B (zh) 吲唑类激酶抑制剂及其用途
CN115485274A (zh) 包含噻唑衍生物或其药学上可接受的盐的用于预防或治疗癌症的药物组合物
CN115996911A (zh) 具有p2x4受体拮抗活性的取代的n-苯乙酰胺

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200106

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200414